Pre-earnings brief
Reports
Mon, Nov 2, 2026
Est. EPS
$-0.50
Est. revenue
$257M
Implied move
±7.5%
EPS beat rate
50%
Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $9 billion, its work is significant as it addresses unmet medical needs in mental health and pain management, areas that are increasingly gaining attention in the healthcare sector.
Last quarter
In Q2 2026, Axsome reported an EPS of $-0.99, slightly missing expectations but showing a smaller loss than anticipated. The stock reacted positively, increasing by 3.83% the following day.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-12.53%
Avg 1-day reaction
+2.76%
Analysts expect Axsome to report a loss this quarter, with a consensus EPS of $-0.50 and revenue of $257 million. The market is watching closely for any signs of improved performance or guidance.
Bull case
If Axsome can beat EPS estimates and show stronger revenue growth, it could signal a turnaround in its financial performance, boosting investor confidence.
Bear case
Conversely, if the company misses expectations again, it may raise concerns about its growth prospects and the viability of its pipeline, leading to a negative market reaction.
Key metrics to watch
EPS
$-0.50Earnings per share (EPS) is crucial as it reflects the company's profitability and helps gauge financial health.
Revenue
$257MRevenue figures indicate the company's ability to generate sales and are a key indicator of business performance.
The print will turn on these.
Q1
Will Axsome's EPS come in better than the consensus estimate of $-0.50?
A better-than-expected EPS could indicate improved operational efficiency and market acceptance of its products.
Q2
What revenue figures can Axsome report compared to the consensus of $257 million?
Revenue performance is critical for assessing the company's growth trajectory and market demand for its therapies.
—
Est. EPS
$8.67
Est. Rev
$660M
Impl. Move
±4.9%
Why consensus could be wrong
The consensus may underestimate the potential for Axsome's pipeline to deliver stronger-than-expected results, particularly in light of recent advancements in their therapies.
Supporting evidence
The stock has shown resilience with positive reactions following previous earnings despite misses.
Options pricing suggests a higher volatility expectation than historical averages, indicating potential for a surprise.
Recent improvements in operational efficiency may not be fully reflected in analyst estimates.
Key risk
If revenue exceeds $270 million, it could challenge the current bearish sentiment and shift market perception.
Pre-commit to what would confirm each case.
This quarter's results are pivotal as they will reveal whether Axsome can overcome recent performance issues and regain investor confidence.
Bull confirmed if
Achieving an EPS of $-0.30 or better would confirm the bull case and suggest a positive trend in financial performance.
Bear confirmed if
An EPS worse than $-0.70 would support the bear case, indicating ongoing challenges in profitability.
What the market is pricing for the move.
Implied Move
±8.65%
Historical Avg
±4.6%
The options market is pricing in a significant move of about 8.65%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±7.5% while AXSM has averaged ±4.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
37.5%
Smart-money positioning from the most recent 13F filings.
Institutional
74.59%
of float
Insider
15.08%
of float
Holders
661
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,103,708 sh · $536.8M
5.93%
-20.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Axsome beats expectations, history suggests a potential stock increase of around 2.93%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity on future guidance.
Miss
A miss could lead to a decline of about 2.59%, reflecting ongoing concerns about the company's growth and profitability.
The lines on the call that would change the story.
Vanguard Portfolio Management LLC
1,983,514 sh · $343.1M
3.79%
-3.6%
Vanguard Capital Management LLC
1,965,086 sh · $339.9M
3.75%
1.4%
Invesco Ltd.
1,671,684 sh · $289.2M
3.19%
28.8%
FMR, LLC
1,539,163 sh · $266.2M
2.94%
-1.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.